Advanced Gene & Cell Technologies

Advanced Gene & Cell Technologies, commonly referred to as AGCT, was a private Russian biotechnology company focused on developing and commercializing genome editing approaches for socially significant diseases. Publicly available company descriptions indicate expertise spanning clinical medicine, oncology, hematology, stem cell transplantation, cell therapy, and molecular biology, with a particular emphasis on HIV-related applications. Third-party pipeline sources list two preclinical gene-therapy programs, AGCT-001 and AGCT Z, both associated with acquired immunodeficiency syndrome. The company appears to have operated in Saint Petersburg, Russia and collaborated with academic institutions including First Pavlov State Medical University of Saint Petersburg and University Medical Center Hamburg-Eppendorf. Available business databases indicate the company is now closed.